lenalidomide has been researched along with Chloroma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cartia, CS; Cazzola, M; Cocito, F; Corso, A; Ferretti, V; Klersy, C; Mangiacavalli, S; Pompa, A; Varettoni, M | 1 |
| Aisa, Y; Ito, C; Mihara, A; Nakazato, T; Sanada, Y | 1 |
2 other study(ies) available for lenalidomide and Chloroma
| Article | Year |
|---|---|
The possible role of burden of therapy on the risk of myeloma extramedullary spread.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Sarcoma, Myeloid; Survival Rate; Thalidomide | 2017 |
Lenalidomide is active for extramedullary disease in refractory multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma; Sarcoma, Myeloid; Thalidomide | 2012 |